<b>Introduction:</b> <i>Neisseria</i> is a large genus of bacteria that colonize mucosal surfaces. Of the 11 species that colonize humans, only two are pathogens, <i>N. meningitidis</i...<b>Introduction:</b> <i>Neisseria</i> is a large genus of bacteria that colonize mucosal surfaces. Of the 11 species that colonize humans, only two are pathogens, <i>N. meningitidis</i> and <i>N. gonorrhoeae</i>. Both are obligate human pathogens;the last is causal agent of gonorrhea disease. Although curable with timely antibiotic treatment, an annual incidence of more than 62 million cases is estimated by the World Health Organization and there are no successful vaccines available. In contrast, several prophylactic vaccine options for <i>Neisseria meningitidis</i> meningitis do exist. Of note, there is trace of cross parenteral response induced between <i>N. meningitidis</i> and <i>N. gonorrhoeae</i>, and Proteoliposome (PL, also named outer membrane vesicles, OMV) vaccine has shown high impact on this response. <b>Objective:</b> To determine effect of VAMENGOC-BC? and its derivates (AFPL1 and AFCo1) at mucosal and systemic level and possible cross response against <i>Neisseria</i> <i>gonhorroeae</i> in Balb/c and C57Bl/6 mice. <b>Methods: </b>We evaluated cross response against <i>N. gonorrhoeae</i> in mouse serum IgG and saliva IgA after mucosal immunization with VA-MENGOC-BC or its derivatives (AF, Adjuvant Finlay PL1 or AFCo (cochleate) 1). <b>Results: </b>Immunizations with AFPL1 or AFCo1 induce anti <i>N. gonorrhoeae</i> at saliva IgA and serum IgG responses similar to VA-MENGOC-BC? vaccine. <b>Conclusions: </b>Such data confirms a new possible window of prime-boost vaccination strategy against gonorrhea and extends our knowledge regarding the effect of PL vaccines on cross responses.展开更多
文摘<b>Introduction:</b> <i>Neisseria</i> is a large genus of bacteria that colonize mucosal surfaces. Of the 11 species that colonize humans, only two are pathogens, <i>N. meningitidis</i> and <i>N. gonorrhoeae</i>. Both are obligate human pathogens;the last is causal agent of gonorrhea disease. Although curable with timely antibiotic treatment, an annual incidence of more than 62 million cases is estimated by the World Health Organization and there are no successful vaccines available. In contrast, several prophylactic vaccine options for <i>Neisseria meningitidis</i> meningitis do exist. Of note, there is trace of cross parenteral response induced between <i>N. meningitidis</i> and <i>N. gonorrhoeae</i>, and Proteoliposome (PL, also named outer membrane vesicles, OMV) vaccine has shown high impact on this response. <b>Objective:</b> To determine effect of VAMENGOC-BC? and its derivates (AFPL1 and AFCo1) at mucosal and systemic level and possible cross response against <i>Neisseria</i> <i>gonhorroeae</i> in Balb/c and C57Bl/6 mice. <b>Methods: </b>We evaluated cross response against <i>N. gonorrhoeae</i> in mouse serum IgG and saliva IgA after mucosal immunization with VA-MENGOC-BC or its derivatives (AF, Adjuvant Finlay PL1 or AFCo (cochleate) 1). <b>Results: </b>Immunizations with AFPL1 or AFCo1 induce anti <i>N. gonorrhoeae</i> at saliva IgA and serum IgG responses similar to VA-MENGOC-BC? vaccine. <b>Conclusions: </b>Such data confirms a new possible window of prime-boost vaccination strategy against gonorrhea and extends our knowledge regarding the effect of PL vaccines on cross responses.
